Table 4.
Progression-free survival by MIPI risk category and by analyzed cohort
| Patient cohort | Median PFS (95% CI), months | Median OS (95% CI), months | ||||
|---|---|---|---|---|---|---|
| Temsirolimus 175/75 mg | Temsirolimus 175/25 mg | INV therapy | Temsirolimus 175/75 mg | Temsirolimus 175/25 mg | INV therapy | |
| Low risk | ||||||
| All | n = 14 | n = 15 | n = 22 | n = 14 | n = 15 | n = 22 |
| 5.3 (4.2, 10.9) | 6.2 (3.5, 10.9) | 2.6 (2.1, 5.4) | 18.0 (11.1, 22.3) | 14.5 (11.0, NA) | 10.5 (6.7, 16.6) | |
| Blastoid excluded | n = 14 | n = 15 | n = 22 | n = 14 | n = 15 | n = 22 |
| 5.3 (4.2, 10.9) | 6.2 (3.5, 10.9) | 2.6 (2.1, 5.4) | 18.0 (11.1, 22.3) | 14.5 (11.0, NA) | 10.5 (6.7, 16.6) | |
| Missing values for MIPI excluded | n = 12 | n = 13 | n = 16 | n = 12 | n = 13 | n = 16 |
| 10.9 (4.2, 10.9) | 6.2 (1.9, 10.9) | 2.9 (2.4, 9.7) | 18.0* (14.1, 22.3) | 14.5 (11.0, NA) | 9.5 (5.3, 16.6) | |
| Blastoid and missing values excluded | n = 12 | n = 13 | n = 16 | n = 12 | n = 13 | n = 16 |
| 10.9 (4.2, 10.9) | 6.2 (1.9, 10.9) | 2.9 (2.4, 9.7) | 18.0* (14.1, 22.3) | 14.5 (11.0, NA) | 9.5 (5.3, 16.6) | |
| Intermediate risk | ||||||
| All | n = 24 | n = 18 | n = 21 | n = 24 | n = 18 | n = 21 |
| 4.3* (2.9, 9.1) | 3.4 (2.6, 3.7) | 1.9 (1.6, 4.0) | 12.8 (8.1, NE) | 8.8 (8.1, 20.6) | 12.4 (5.7, 15.1) | |
| Blastoid excluded | n = 24 | n = 16 | n = 19 | n = 24 | n = 16 | n = 19 |
| 4.3 (2.9, 9.1) | 3.4 (1.8, 7.0) | 1.9 (1.6, 4.0) | 12.8 (8.1, NA) | 8.8 (8.1, 20.6) | 13.6 (5.7, NA) | |
| Missing values for MIPI excluded | n = 22 | n = 18 | n = 19 | n = 22 | n = 18 | n = 19 |
| 4.8* (3.1, 9.1) | 3.4 (2.6, 3.7) | 1.9 (1.3, 4.0) | 14.3 (10.0, NA) | 8.8 (8.1, 20.6) | 12.4 (5.7, 15.1) | |
| Blastoid and missing values excluded | n = 22 | n = 16 | n = 17 | n = 22 | n = 16 | n = 17 |
| 4.8* (3.1, 9.1) | 3.4 (1.8, 7.0) | 1.9 (1.3, 4.6) | 14.3 (10.0, NA) | 8.8 (8.1, 20.6) | 12.4 (5.7, NA) | |
| High risk | ||||||
| All | n = 16 | n = 21 | n = 11 | n = 16 | n = 21 | n = 11 |
| 4.5† (1.7, 7.4) | 1.9 (1.5, 3.3) | 1.6 (0.7, 1.7) | 5.3 (2.0, 9.9) | 4.1 (2.0, 7.2) | 3.5 (2.0, 4.8) | |
| Blastoid excluded | n = 16 | n = 14 | n = 9 | n = 16 | n = 14 | n = 9 |
| 4.5‡ (1.7, 7.4) | 1.9* (1.7, 5.6) | 1.6 (0.9, 1.7) | 5.3 (2.0, 9.9) | 5.1 (3.3, 14.6) | 3.7 (3.2, 20.4) | |
| Missing values for MIPI excluded | n = 16 | n = 18 | n = 11 | n = 16 | n = 18 | n = 11 |
| 4.5† (1.7, 7.4) | 1.9* (1.5, 3.3) | 1.6 (0.7, 1.7) | 5.3 (2.0, 9.9) | 4.5 (3.3, 7.2) | 3.5 (2.0, 4.8) | |
| Blastoid and missing values excluded | n = 16 | n = 12 | n = 9 | n = 16 | n = 12 | n = 9 |
| 4.5‡ (1.7, 7.4) | 1.9* (1.7, 5.6) | 1.6 (0.9, 1.7) | 5.3 (2.0, 9.9) | 5.1 (3.3, 14.6) | 3.7 (3.2, 20.4) | |
* P < 0.05 versus INV.
† P < 0.005 versus INV.
‡ P < 0.01 versus INV.
MIPI = Mantle Cell Lymphoma International Prognostic Index; PFS = progression-free survival; CI = confidence interval; OS = overall survival; INV = Investigator’s choice of therapy.